Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtype
Background: Conditional relative survival (CRS), the probability of survival given that an individual has already survived a certain period post-diagnosis, is a more clinically relevant measure for long-term survival than standard relative survival (RS). This study aims to evaluate the 5-year CRS am...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Journal of the National Cancer Center |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667005425000407 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839650276100800512 |
|---|---|
| author | Noëlle J.M.C. Vrancken Peeters Daniël J. van der Meer Marleen Kok Marissa C. van Maaren Marie-Jeanne T.F.D. Vrancken Peeters Sabine Siesling Winette T.A. van der Graaf Olga Husson |
| author_facet | Noëlle J.M.C. Vrancken Peeters Daniël J. van der Meer Marleen Kok Marissa C. van Maaren Marie-Jeanne T.F.D. Vrancken Peeters Sabine Siesling Winette T.A. van der Graaf Olga Husson |
| author_sort | Noëlle J.M.C. Vrancken Peeters |
| collection | DOAJ |
| description | Background: Conditional relative survival (CRS), the probability of survival given that an individual has already survived a certain period post-diagnosis, is a more clinically relevant measure for long-term survival than standard relative survival (RS). This study aims to evaluate the 5-year CRS among adolescent and young adult (AYA) breast cancer patients by age, tumor stage, and receptor subtype to guide disclosure periods for insurance. Methods: Data of all females aged 18–39 years and diagnosed with invasive breast cancer between 2003 and 2021 (n = 13,075) were obtained from The Netherlands Cancer Registry (NCR). The five-year CRS was calculated annually up to 10 years post-diagnosis using a hybrid analysis approach. Results: For the total AYA breast cancer study population the 5-year CRS exceeded 90 % from diagnosis and increased beyond 95 % 7 years post-diagnosis. Patients aged 18–24 reached 95 % 9 years post-diagnosis, those aged 25–29 after 5 years, and those aged 30–34 and 35–39 after 8 years. For stage I, the 5-year CRS reached 95 % from diagnosis, for stage II after 6 years, while the 5-year CRS for stages III and IV did not reach the 95 % threshold during the 10-year follow-up. Triple-negative tumors exceeded 95 % after 4 years, human epidermal growth factor receptor 2 (HER2) positive tumors after 6 years, while hormone receptor (HR) positive tumors did not reach 95 %. Conclusion: Excess mortality among AYA breast cancer patients tends to be little (CRS 90 %–95 %) from diagnosis and becomes minimal (CRS>95 %) over time compared to the general population. These results can enhance expectation management and inform policymakers, suggesting a shorter disclosure period. |
| format | Article |
| id | doaj-art-a80f99acba87413c8a360fcf1726a1c8 |
| institution | Matheson Library |
| issn | 2667-0054 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the National Cancer Center |
| spelling | doaj-art-a80f99acba87413c8a360fcf1726a1c82025-06-27T05:52:30ZengElsevierJournal of the National Cancer Center2667-00542025-06-0153297305Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtypeNoëlle J.M.C. Vrancken Peeters0Daniël J. van der Meer1Marleen Kok2Marissa C. van Maaren3Marie-Jeanne T.F.D. Vrancken Peeters4Sabine Siesling5Winette T.A. van der Graaf6Olga Husson7Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands; Department of Plastic and Reconstructive Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands; Department of Surgical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The NetherlandsDepartment of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The NetherlandsDepartment of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands; Division of Tumor Biology & Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The NetherlandsDepartment of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The NetherlandsDepartment of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands; Department of Surgery, Amsterdam UMC, Amsterdam, The NetherlandsDepartment of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The NetherlandsDepartment of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The NetherlandsDepartment of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands; Department of Surgical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands; Department of Public Health, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands; Corresponding author.Background: Conditional relative survival (CRS), the probability of survival given that an individual has already survived a certain period post-diagnosis, is a more clinically relevant measure for long-term survival than standard relative survival (RS). This study aims to evaluate the 5-year CRS among adolescent and young adult (AYA) breast cancer patients by age, tumor stage, and receptor subtype to guide disclosure periods for insurance. Methods: Data of all females aged 18–39 years and diagnosed with invasive breast cancer between 2003 and 2021 (n = 13,075) were obtained from The Netherlands Cancer Registry (NCR). The five-year CRS was calculated annually up to 10 years post-diagnosis using a hybrid analysis approach. Results: For the total AYA breast cancer study population the 5-year CRS exceeded 90 % from diagnosis and increased beyond 95 % 7 years post-diagnosis. Patients aged 18–24 reached 95 % 9 years post-diagnosis, those aged 25–29 after 5 years, and those aged 30–34 and 35–39 after 8 years. For stage I, the 5-year CRS reached 95 % from diagnosis, for stage II after 6 years, while the 5-year CRS for stages III and IV did not reach the 95 % threshold during the 10-year follow-up. Triple-negative tumors exceeded 95 % after 4 years, human epidermal growth factor receptor 2 (HER2) positive tumors after 6 years, while hormone receptor (HR) positive tumors did not reach 95 %. Conclusion: Excess mortality among AYA breast cancer patients tends to be little (CRS 90 %–95 %) from diagnosis and becomes minimal (CRS>95 %) over time compared to the general population. These results can enhance expectation management and inform policymakers, suggesting a shorter disclosure period.http://www.sciencedirect.com/science/article/pii/S2667005425000407Adolescents and young adults (AYAS)Breast cancerConditional relative survival (CRS)Excess mortalityRelative survival (RS)Survivorship |
| spellingShingle | Noëlle J.M.C. Vrancken Peeters Daniël J. van der Meer Marleen Kok Marissa C. van Maaren Marie-Jeanne T.F.D. Vrancken Peeters Sabine Siesling Winette T.A. van der Graaf Olga Husson Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtype Journal of the National Cancer Center Adolescents and young adults (AYAS) Breast cancer Conditional relative survival (CRS) Excess mortality Relative survival (RS) Survivorship |
| title | Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtype |
| title_full | Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtype |
| title_fullStr | Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtype |
| title_full_unstemmed | Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtype |
| title_short | Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtype |
| title_sort | five year conditional relative survival up to 10 years post diagnosis among adolescent and young adult breast cancer patients by age stage and receptor subtype |
| topic | Adolescents and young adults (AYAS) Breast cancer Conditional relative survival (CRS) Excess mortality Relative survival (RS) Survivorship |
| url | http://www.sciencedirect.com/science/article/pii/S2667005425000407 |
| work_keys_str_mv | AT noellejmcvranckenpeeters fiveyearconditionalrelativesurvivalupto10yearspostdiagnosisamongadolescentandyoungadultbreastcancerpatientsbyagestageandreceptorsubtype AT danieljvandermeer fiveyearconditionalrelativesurvivalupto10yearspostdiagnosisamongadolescentandyoungadultbreastcancerpatientsbyagestageandreceptorsubtype AT marleenkok fiveyearconditionalrelativesurvivalupto10yearspostdiagnosisamongadolescentandyoungadultbreastcancerpatientsbyagestageandreceptorsubtype AT marissacvanmaaren fiveyearconditionalrelativesurvivalupto10yearspostdiagnosisamongadolescentandyoungadultbreastcancerpatientsbyagestageandreceptorsubtype AT mariejeannetfdvranckenpeeters fiveyearconditionalrelativesurvivalupto10yearspostdiagnosisamongadolescentandyoungadultbreastcancerpatientsbyagestageandreceptorsubtype AT sabinesiesling fiveyearconditionalrelativesurvivalupto10yearspostdiagnosisamongadolescentandyoungadultbreastcancerpatientsbyagestageandreceptorsubtype AT winettetavandergraaf fiveyearconditionalrelativesurvivalupto10yearspostdiagnosisamongadolescentandyoungadultbreastcancerpatientsbyagestageandreceptorsubtype AT olgahusson fiveyearconditionalrelativesurvivalupto10yearspostdiagnosisamongadolescentandyoungadultbreastcancerpatientsbyagestageandreceptorsubtype |